Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
said it was informed today that the U.S. Food and Drug Administration
(FDA) has cancelled the meeting of the Anesthetic and Analgesic Drug
Products Advisory Committee scheduled for March 18, 2015. The committee
had planned to discuss the resubmission of the New Drug Application
(NDA) for sugammadex injection, Merck’s investigational medicine for the
reversal of neuromuscular blockade induced by rocuronium or vecuronium.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Anesthesia | Anesthesiology | Food and Drug Administration (FDA) | Merck | Neurology | New Drug Applications | Pharmaceuticals